Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement

MeSH terms

• Agammaglobulinaemia Tyrosine Kinase* / antagonists & inhibitors
• Aged
• Central Nervous System Neoplasms* / drug therapy
• Central Nervous System Neoplasms* / therapy
• Combined Modality Therapy
• Female
• Humans
• Immunotherapy, Adoptive* / adverse effects
• Immunotherapy, Adoptive* / methods
• Lymphoma, Mantle-Cell* / drug therapy
• Lymphoma, Mantle-Cell* / pathology
• Lymphoma, Mantle-Cell* / therapy
• Male
• Middle Aged
• Neoplasm Recurrence, Local / drug therapy
• Protein Kinase Inhibitors* / adverse effects
• Protein Kinase Inhibitors* / therapeutic use
• Receptors, Chimeric Antigen
• Treatment Outcome